Enterolactone Inhibits Insulin-Like Growth Factor-1 Receptor Signaling in Human Prostatic Carcinoma PC-3 Cells
Authors:
- 1 April 2009
- journal article
- research article
- Published by Elsevier in The Journal of Nutrition
- Vol. 139 (4) , 653-659
Abstract
Enterolactone, a major metabolite of plant-based lignans, has been shown to inhibit prostate cancer growth and development, but the mechanistic basisKeywords
This publication has 47 references indexed in Scilit:
- Flaxseed Supplementation (Not Dietary Fat Restriction) Reduces Prostate Cancer Proliferation Rates in Men PresurgeryCancer Epidemiology, Biomarkers & Prevention, 2008
- Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate CancerJNCI: Journal of the National Cancer Institute, 2002
- Effect of mammalian lignans on the growth of prostate cancer cell lines.2002
- In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).2001
- Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic featuresUrology, 2001
- Insulin-like Growth Factors and Prostate CancerEpidemiologic Reviews, 2001
- Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective StudyJNCI: Journal of the National Cancer Institute, 2000
- Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic miceProceedings of the National Academy of Sciences, 2000
- Insulin-like growth factor I receptor signalling in prostate cancer cellsGrowth Hormone & IGF Research, 2000
- Oxidative Metabolism of the Mammalian Lignans Enterolactone and Enterodiol by Rat, Pig, and Human Liver MicrosomesJournal of Agricultural and Food Chemistry, 1999